ReviewFrontiers in immunology2025
Exploring research trends in cancer immunotherapy via single-cell technologies: a scientometric perspective.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Segmental analysis of esophageal and gastric fundus microbiome diversity in reflux esophagitis.Folia microbiologica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cancer immunotherapy has brought new therapeutic hopes for cancer patients, but it is complex in its mechanism of action, and there are significant individual differences, which restricts its wide use. As single-cell analysis technology develops rapidly, it provides an innovative research approach to investigate immunotherapy mechanisms, to identify potential biomarkers, and to optimize individualized treatment strategies. Methods: The Core Collection of Web of Science (WOSCC) was used to retrieve and obtain relevant literature related to "application of single cell sequencing in cancer immunotherapy" since the establishment of the WOSCC. A quantitative analysis and visualization of the related literature was conducted using tools such as Bibliometrix, Excel, CiteSpace, VOSviewer, and Scimago Graphica. Results: The total number of related literatures included was 4856, with an average annual growth rate of 25.14%. According to published articles, China and the United States lead the field. Frontiers in immunology, Nature Communications, Journal for Immunotherapy of Cancer, Scientific Reports, Frontiers in Oncology and Cancers have an important academic influence in this field. Research hotspots focus on tumor immune microenvironment and cellular heterogeneity. Research trends such as spatial transcriptomics, standardized processes, and T cell function are becoming increasingly popular. Conclusion: In tumor immunotherapy, single-cell sequencing is profoundly changing the research paradigm. It not only improves our understanding of the immune microenvironment and therapeutic heterogeneity, but also assists us in identifying accurate markers and formulating individualized treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.